Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.

Keay Nakae’s rating is based on Avidity Biosciences’ strategic focus on genetically validated targets for cardiomyopathies using their proprietary antibody oligonucleotide conjugate (AOC) technology.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-reports-third-quarter-2024-financial-results-and-recent ...

SAN DIEGO, Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ: RNA) has announced the commencement of a biomarker cohort for its Phase 1/2 FORTITUDE trial, which is evaluating delpacibart braxlosiran (del-brax ...

Revenue: US$2.34m (down 17% from 3Q 2023). Net loss: US$80.4m (loss widened by 54% from 3Q 2023). US$0.65 loss per share. Revenue missed analyst estimates by 49%. Earnings per share (EPS) exceeded ...